Share: Facebook Twitter LinkedIn
Activity Provided By:

Physicians’ Education Resource®, LLC

Collaborating Across the Continuum™: Taking IgA Nephropathy Management to the Next Level

Access Activity

Overview / Abstract:

Target Audience
This activity is intended for nephrologists, primary care providers, specialty pharmacists, managed care professionals, nurse practitioners, physician assistants, registered nurses, and other members of the IgAN care team.

Activity Overview
Immunoglobulin (Ig) A nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide, and it is considered a significant cause of end-stage renal disease (ESRD) in young adults. The precise pathogenesis of IgAN remains unclear. The clinical and pathological features vary significantly between individuals and races, which makes treating IgAN challenging. In most cases, the therapeutic strategies in IgAN are optimal blood pressure control and proteinuria remission to improve the renal functions. Immunosuppressive agents, such as corticosteroids, can be considered in patients with persistent proteinuria and a high risk of renal function decline; however, they include a high toxicity profile.

Various pharmacological therapeutic targets are emerging based on the evolving understanding of the autoimmune pathogenesis of the progression of IgAN, which involves the immune response, mucosal immunity, renal inflammation, complement activation, and autophagy. In this online activity, expert faculty provide information to help health care providers stay up to date on recent findings regarding the pathophysiology of IgAN, and the efficacy and safety profiles of available and emerging agents.

Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
Assess the pathophysiology of the disease progression of IgAN as potential targets for novel therapy
Summarize recent evidence-based guidelines for the management of IgAN
Analyze recent efficacy and safety trial data on new and emerging treatment for IgAN
Design individualized treatment plans for patients with IgAN based on principles of multidisciplinary care

Expiration

Jan 31, 2024

Discipline(s)

Physician CME

Format

Online

Credits / Hours

1.5

Accreditation

ACCME, ACPE

Presenters / Authors / Faculty

Richard Lafayette, MD, FACP
Whitney Simmons, APRN-CNP, IgCN
Michelle M. Richardson, PharmD, BCPS

Sponsors / Supporters / Grant Providers

Travere Therapeutics

Keywords / Search Terms

Relias LLC Relias, Free CME, IgAN Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map